Number of Clinical Trials 2013
Explore the number of clinical trials conducted in various countries; critical for medical research and innovation.
Newer data is available: Number of Clinical Trials by country 2024 →
Where does your country rank? Pick it to see its position.
Related Health statistics
More ↓Interactive Map
Complete Data Rankings
- #1
United States
- #2
France
- #3
Germany
- #4
Canada
- #5
South Korea
- #6
United Kingdom
- #7
China
- #8
Denmark
- #9
Italy
- #10
Spain
Analysis: These countries represent the highest values in this dataset, showcasing significant scale and impact on global statistics.
- #124
Sierra Leone
- #123
State of Palestine
- #122
Oman
- #121
Nicaragua
- #120
Morocco
- #119
Mongolia
- #118
Republic of Moldova
- #117
Liberia
- #116
Latvia
- #115
Kyrgyzstan
Context: These countries or territories have the lowest values, often due to geographic size, administrative status, or specific characteristics.
Insights by country
Belgium
In 2013, Belgium ranked #14 globally with a total of 155 clinical trials. This figure is notable compared to its neighbor, the Netherlands, which had a similar focus on research but ranked lower in clinical trial numbers. Belgium's robust pharmaceutical sector, coupled with its strategic location in Europe and strong regulatory framework, drives this high level of clinical research activity.
Portugal
In 2013, Portugal ranked #42 globally with a total of 19 clinical trials. This figure is notably lower than the European average, reflecting a more cautious approach to clinical research compared to leading countries like Germany, which boasts significantly higher trial numbers. Factors contributing to this statistic include Portugal's relatively smaller population and a healthcare system that prioritizes public health over extensive clinical research initiatives.
Finland
In 2013, Finland ranked #29 globally with a total of 48 clinical trials. This figure is notably higher than the bottom-ranked country, which reported no trials, indicating Finland's active role in clinical research. Contributing factors include a strong healthcare system, a well-educated population, and supportive government policies that promote innovation in medical research.
Taiwan
Taiwan ranked #15 globally with 154 clinical trials in 2013. This figure reflects a robust commitment to medical research, particularly in comparison to regional peers like South Korea, which has a higher number of trials. The country's advanced healthcare system, strong emphasis on biotechnology, and supportive government policies have fostered a conducive environment for clinical research.
Israel
In 2013, Israel ranked #19 globally with a total of 119 clinical trials. This figure is notable compared to the global average, reflecting Israel's robust position in the field of medical research. The country's advanced healthcare system, significant investment in biotechnology, and a strong network of academic institutions drive its high level of clinical trial activity.
Guatemala
In 2013, Guatemala ranked #107 globally with a total of 1 clinical trial. This figure is significantly lower than many of its regional peers, highlighting the country's limited involvement in clinical research compared to countries with more developed healthcare infrastructures. Factors contributing to this low number include economic constraints, a lack of investment in research and development, and challenges in regulatory frameworks that can hinder the initiation of clinical trials.
India
In 2013, India ranked #21 globally with 93 clinical trials. This figure is notable compared to neighboring countries like Pakistan, which had fewer trials during the same period. India's robust pharmaceutical industry, combined with a large and diverse patient population, drives this high number of clinical trials, facilitating faster drug development and testing.
Argentina
In 2013, Argentina ranked #34 globally with a total of 28 clinical trials. This number is relatively low compared to regional leaders such as Brazil, which has a more robust clinical research infrastructure. Argentina's position reflects its developing healthcare system and regulatory environment, which can impact the attractiveness of the country for international clinical research investments.
Bahrain
Bahrain ranked #97 globally with a total of 1 clinical trial in 2013. This number is significantly lower than many of its regional peers, reflecting the challenges Bahrain faces in establishing a robust clinical research infrastructure.
The limited number of clinical trials can be attributed to its smaller population and relatively nascent healthcare research sector, which may not attract as much investment or interest compared to larger countries in the Gulf region.
Hungary
In 2013, Hungary ranked #35 globally with a total of 24 clinical trials. This figure is notable compared to neighboring countries, as Hungary's clinical trial activity is relatively robust in the Central European region. The country benefits from a well-established healthcare system and a skilled workforce, which attract pharmaceutical companies seeking efficient trial locations.
Analysis & Context
In 2013, the United States led the world in the Number of Clinical Trials with a staggering figure of 4893, while globally, the number of trials ranged from 1 to 4893 across 124 countries. The global median for clinical trials was 7, indicating a significant skew towards a few countries conducting the majority of trials.
Concentration of Clinical Trials in Developed Countries
The distribution of clinical trials in 2013 reveals a strong concentration in developed countries, with the United States far ahead at 4893 trials. Other leading nations include France with 618 trials and Germany with 550. This pattern is largely driven by the advanced healthcare infrastructure, substantial investment in research and development, and the presence of leading pharmaceutical companies in these countries. The European Union's regulatory environment, which facilitates multinational trials, also contributes to high numbers in France and Germany.
Emerging Players in Clinical Trials
Some countries are emerging as significant players in clinical trials despite not leading the pack. South Korea and China are notable, with 443 and 334 trials respectively. South Korea's robust increase by 61 trials (16.0%) from the previous year highlights its growing role in global medical research. This growth can be attributed to government incentives for clinical research and a strong technological base. Similarly, China is leveraging its vast population and rapid economic growth to become a hub for clinical trials.
Challenges in Low-Performing Regions
At the other end of the spectrum, countries like Republic of Moldova, Mongolia, and American Samoa recorded only 1 clinical trial each in 2013. These low numbers often reflect limited healthcare infrastructure, fewer financial resources for research, and less access to international research networks. The minimal presence of clinical trials in these countries could hinder their ability to access cutting-edge medical therapies and innovations.
Year-over-Year Trends and Their Implications
Analyzing year-over-year changes, several countries experienced significant shifts. France saw the largest increase, adding 107 trials (20.9%), likely due to enhanced research funding and collaborations. In contrast, India experienced a decrease of 36 trials (-27.9%), potentially due to regulatory challenges and concerns over trial ethics. Similarly, Brazil and the Netherlands saw declines of 23 and 16 trials respectively, indicating possible fluctuations in research funding or policy changes affecting trial approvals.
The global landscape of clinical trials in 2013 highlights significant disparities between countries, driven by economic, regulatory, and infrastructural factors. While developed nations dominate the scene, emerging economies are making strides, and the challenges faced by low-performing regions underscore the need for international support and investment in global healthcare research capabilities.
Frequently Asked Questions About Number of Clinical Trials in 2013
Which country had the highest number of clinical trials in 2013?
The United States had the highest number of clinical trials in 2013, with a total of 4,893.
Which country had the lowest number of clinical trials in 2013?
The Republic of Moldova had the lowest number of clinical trials in 2013, with just 1 trial.
What was the average number of clinical trials conducted per country in 2013?
The average number of clinical trials conducted per country in 2013 was 91.77.
What was the median number of clinical trials conducted by countries in 2013?
The median number of clinical trials conducted by countries in 2013 was 7.
Which countries were in the top 3 for the number of clinical trials in 2013?
The top 3 countries for the number of clinical trials in 2013 were the United States with 4,893, France with 618, and Germany with 550.
How many countries conducted only 1 clinical trial in 2013?
Ten countries conducted only 1 clinical trial in 2013, including the Republic of Moldova and Mongolia.
Data Source
Number of clinical trials | ClinicalTrials.gov via Our World in Data
Data produced by ClinicalTrials.gov, compiled and published by Our World in Data as "Number of clinical trials".
Visit Data SourceCite this page
Geo Factbook. (n.d.). Number of Clinical Trials by Country, 2013. Retrieved November 16, 2026, from https://geofactbook.com/fact/number-of-clinical-trials/2013
The figures on this page come from Number of clinical trials | ClinicalTrials.gov via Our World in Data. For academic work, cite the original source as well.
›Embed this ranking on your site
Free to embed with attribution. Shows the top 10 countries and links back to the full ranking.